October 9th 2023
The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.
NORD Report: COVID-19 Telehealth Surge Especially Important for People With Rare Diseases
November 12th 2020Telehealth during the COVID-19 pandemic has been especially important to patients with rare disorders, many of which are autoimmune diseases, according to a recent report from the National Organization for Rare Disorders.
Read More
Time to Revise Hydroxychloroquine, Retinopathy Guidelines, Say Authors
October 21st 2020Rather than stopping hydroxychloroquine altogether, doses could be reduced and patients monitored if there are signs of retinopathy, say the authors of a commentary in the American Journal of Ophthalmology.
Read More